HK1208231A1 - 類風濕性關節炎之治療 - Google Patents

類風濕性關節炎之治療

Info

Publication number: HK1208231A1
Authority: HK; Hong Kong
Prior art keywords: treatment; rheumatoid arthritis; rheumatoid; arthritis
Prior art date: 2012-09-20

Application number

HK15108769.5A

Other languages

English (en)

Inventor

Stefan Haertle

Stephane Leclair

Amgad Shebl

Stefan Steidl

Original Assignee

Morphosys Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-20

Filing date

2015-09-09

Publication date

2016-02-26

2015-09-09 Application filed by Morphosys Ag filed Critical Morphosys Ag

2016-02-26 Publication of HK1208231A1 publication Critical patent/HK1208231A1/zh

Links

206010039073 rheumatoid arthritis Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
Microbiology (AREA)
Mycology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

HK15108769.5A 2012-09-20 2015-09-09 類風濕性關節炎之治療 HK1208231A1 (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP12185235		2012-09-20
US201261703871P	2012-09-21	2012-09-21
PCT/EP2013/069501 WO2014044768A1 (en)	2012-09-20	2013-09-19	Treatment for rheumatoid arthritis

Publications (1)

Publication Number	Publication Date
HK1208231A1 true HK1208231A1 (zh)	2016-02-26

Family

ID=46963526

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK15108769.5A HK1208231A1 (zh)	2012-09-20	2015-09-09	類風濕性關節炎之治療

Country Status (23)

Country	Link
US (3)	US20150246969A1 (zh)
EP (3)	EP3916013A1 (zh)
JP (3)	JP2015533806A (zh)
KR (3)	KR20230041086A (zh)
CN (2)	CN104995210A (zh)
AU (2)	AU2013320261A1 (zh)
BR (1)	BR112015006189B1 (zh)
CA (1)	CA2884124A1 (zh)
CL (2)	CL2015000696A1 (zh)
CR (1)	CR20150153A (zh)
DO (1)	DOP2015000070A (zh)
EA (1)	EA031489B1 (zh)
HK (1)	HK1208231A1 (zh)
IL (1)	IL237554B (zh)
IN (1)	IN2015KN00657A (zh)
MA (1)	MA37946B1 (zh)
MX (2)	MX2015003644A (zh)
MY (1)	MY175388A (zh)
PE (1)	PE20151079A1 (zh)
PH (1)	PH12015500591A1 (zh)
SG (2)	SG11201501595YA (zh)
UA (1)	UA117228C2 (zh)
WO (1)	WO2014044768A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3916013A1 (en) *	2012-09-20	2021-12-01	MorphoSys AG	Treatment for rheumatoid arthritis with anti-gm-csf antibody
AR093297A1 (es)	2012-10-31	2015-05-27	Amgen Res (Munich) Gmbh	Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US9833410B2 (en)	2012-10-31	2017-12-05	Takeda Gmbh	Lyophilized formulation comprising GM-CSF neutralizing compound
WO2015028657A1 (en)	2013-08-30	2015-03-05	Takeda Gmbh	Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
US11299528B2 (en) *	2014-03-11	2022-04-12	D&D Pharmatech Inc.	Long acting TRAIL receptor agonists for treatment of autoimmune diseases
US11173208B2 (en) *	2014-05-07	2021-11-16	Takeda Gmbh	Liquid formulation comprising GM-CSF neutralizing compound
GB201519331D0 (en) *	2015-11-02	2015-12-16	Glaxosmithkline Ip Dev Ltd	Treatment paradigm
CA3008392C (en)	2015-12-17	2021-11-09	The Johns Hopkins University	Ameliorating systemic sclerosis with death receptor agonists
CA3020339C (en)	2016-04-07	2022-05-03	The Johns Hopkins University	Compositions and methods for treating pancreatitis and pain with death receptor agonists
BR112019005274A2 (pt) *	2016-09-19	2019-06-04	I Mab	anticorpo isolado ou fragmento do mesmo, composição, célula isolada, e, métodos para tratar uma doença ou condição inflamatória ou autoimune, para tratar um câncer, para reduzir ou aliviar dor e para detectar expressão de gm-csf em uma amostra.
US11655293B2 (en) *	2018-02-22	2023-05-23	Universitat Zurich	Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en)	2018-09-14	2020-03-18	Universität Zürich	Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
WO2021204649A1 (en)	2020-04-06	2021-10-14	Glaxosmithkline Intellectual Property Development Limited	Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
KR100408229B1 (ko)	1996-10-04	2003-12-01	암겐 인코포레이티드	Ｍｐｌ 리간드를 함유하는 제약학적 조성물
US7455836B2 (en)	2000-05-08	2008-11-25	The University Of Melbourne	Method of treatment and agents useful for same
NZ564027A (en) *	2005-05-18	2011-06-30	Morphosys Ag	Anti-GM-CSF antibodies and uses therefor
WO2007037795A2 (en)	2005-08-05	2007-04-05	Amgen Inc.	Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US9399061B2 (en) *	2006-04-10	2016-07-26	Abbvie Biotechnology Ltd	Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2008042261A2 (en) *	2006-09-28	2008-04-10	Elusys Therapeutics, Inc.	Anti-anthrax antibody, formulations thereof, and methods of use
NZ598345A (en) *	2006-11-21	2013-09-27	Kalobios Pharmaceuticals Inc	Methods of treating chronic inflammatory diseases using a gm-csf antagonist
RU2491094C2 (ru) *	2007-03-30	2013-08-27	Медиммун, Ллк	Препарат антитела
WO2008122007A1 (en) *	2007-04-02	2008-10-09	Genentech, Inc.	Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
AU2008235044B2 (en)	2007-04-05	2011-08-25	Sandoz Ag	Stable aqueous G-CSF formulations
US20090004189A1 (en) *	2007-06-18	2009-01-01	Genentech, Inc.	Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
TW200918553A (en) *	2007-09-18	2009-05-01	Amgen Inc	Human GM-CSF antigen binding proteins
ES2401536T3 (es) *	2007-11-13	2013-04-22	Evec Inc.	Anticuerpos monoclonales que se unen a HGM-CSF y composiciones medicinales que los comprenden
EP2196476A1 (en) *	2008-12-10	2010-06-16	Novartis Ag	Antibody formulation
US8475796B2 (en)	2008-12-22	2013-07-02	University Of Melbourne	Method of treating pain using an antagonist of GM-CSF
CN106397591A (zh)	2008-12-22	2017-02-15	墨尔本大学	骨关节炎治疗
JP2010241718A (ja)	2009-04-03	2010-10-28	Kyowa Hakko Kirin Co Ltd	安定な抗体の水溶液製剤
US20120116059A1 (en) *	2009-05-05	2012-05-10	Morphosys Ag	Treatment For M Treatment For Multiple Sclerosis
PT2341061E (pt)	2009-12-31	2013-11-05	Arven Ilac Sanayi Ve Ticaret As	Um processo novo para a preparação de g-csf (fator de estimulação de colónias de granulócitos)
NZ602685A (en) *	2010-03-01	2014-10-31	Cytodyn Inc	Concentrated protein formulations and uses thereof
CA2839513A1 (en)	2011-07-06	2013-01-10	Morphosys Ag	Therapeutic combinations of anti - cd20 and anti - gm - csf antibodies and uses thereof
EP3916013A1 (en) *	2012-09-20	2021-12-01	MorphoSys AG	Treatment for rheumatoid arthritis with anti-gm-csf antibody

2013
- 2013-09-19 EP EP21169696.8A patent/EP3916013A1/en active Pending
- 2013-09-19 CN CN201380049042.8A patent/CN104995210A/zh active Pending
- 2013-09-19 PE PE2015000350A patent/PE20151079A1/es unknown
- 2013-09-19 MX MX2015003644A patent/MX2015003644A/es unknown
- 2013-09-19 US US14/429,996 patent/US20150246969A1/en not_active Abandoned
- 2013-09-19 AU AU2013320261A patent/AU2013320261A1/en not_active Abandoned
- 2013-09-19 CN CN201811553113.9A patent/CN109999195A/zh active Pending
- 2013-09-19 MA MA37946A patent/MA37946B1/fr unknown
- 2013-09-19 KR KR1020237008704A patent/KR20230041086A/ko not_active Application Discontinuation
- 2013-09-19 KR KR1020157009911A patent/KR20150056846A/ko active Application Filing
- 2013-09-19 MY MYPI2015700862A patent/MY175388A/en unknown
- 2013-09-19 KR KR1020227006147A patent/KR20220028177A/ko not_active Application Discontinuation
- 2013-09-19 EP EP18155371.0A patent/EP3345923A1/en not_active Withdrawn
- 2013-09-19 SG SG11201501595YA patent/SG11201501595YA/en unknown
- 2013-09-19 IN IN657KON2015 patent/IN2015KN00657A/en unknown
- 2013-09-19 JP JP2015532412A patent/JP2015533806A/ja active Pending
- 2013-09-19 EA EA201590359A patent/EA031489B1/ru unknown
- 2013-09-19 BR BR112015006189-3A patent/BR112015006189B1/pt active IP Right Grant
- 2013-09-19 EP EP13763100.8A patent/EP2897977A1/en not_active Withdrawn
- 2013-09-19 CA CA2884124A patent/CA2884124A1/en active Pending
- 2013-09-19 UA UAA201502131A patent/UA117228C2/uk unknown
- 2013-09-19 WO PCT/EP2013/069501 patent/WO2014044768A1/en active Application Filing
- 2013-09-19 SG SG10201803778PA patent/SG10201803778PA/en unknown
2015
- 2015-03-04 IL IL237554A patent/IL237554B/en active IP Right Grant
- 2015-03-18 PH PH12015500591A patent/PH12015500591A1/en unknown
- 2015-03-19 CL CL2015000696A patent/CL2015000696A1/es unknown
- 2015-03-20 MX MX2021006111A patent/MX2021006111A/es unknown
- 2015-03-20 CR CR20150153A patent/CR20150153A/es unknown
- 2015-03-20 DO DO2015000070A patent/DOP2015000070A/es unknown
- 2015-09-09 HK HK15108769.5A patent/HK1208231A1/zh unknown
2016
- 2016-10-26 AU AU2016250388A patent/AU2016250388B2/en active Active
2018
- 2018-01-26 US US15/880,726 patent/US10913792B2/en active Active
- 2018-03-28 JP JP2018061614A patent/JP2018138551A/ja active Pending
- 2018-04-12 CL CL2018000933A patent/CL2018000933A1/es unknown
2021
- 2021-01-08 US US17/144,685 patent/US20210130451A1/en active Pending
2022
- 2022-08-25 JP JP2022133957A patent/JP2022169709A/ja active Pending

Also Published As

Publication number	Publication date
JP2015533806A (ja)	2015-11-26
CL2015000696A1 (es)	2015-10-23
SG10201803778PA (en)	2018-06-28
BR112015006189B1 (pt)	2022-04-05
EP3345923A1 (en)	2018-07-11
JP2018138551A (ja)	2018-09-06
IL237554B (en)	2019-12-31
MX2021006111A (es)	2021-07-07
PE20151079A1 (es)	2015-08-07
US20150246969A1 (en)	2015-09-03
MA37946B1 (fr)	2018-09-28
PH12015500591B1 (en)	2015-05-11
AU2016250388A1 (en)	2016-11-17
CL2018000933A1 (es)	2018-07-20
MA37946A1 (fr)	2018-01-31
PH12015500591A1 (en)	2015-05-11
AU2016250388B2 (en)	2018-07-19
CR20150153A (es)	2015-09-14
EA201590359A1 (ru)	2015-08-31
MX2015003644A (es)	2015-09-25
CN104995210A (zh)	2015-10-21
BR112015006189A2 (pt)	2019-11-26
DOP2015000070A (es)	2015-08-16
MY175388A (en)	2020-06-23
SG11201501595YA (en)	2015-05-28
EP3916013A1 (en)	2021-12-01
KR20150056846A (ko)	2015-05-27
AU2013320261A1 (en)	2015-04-09
EA031489B1 (ru)	2019-01-31
US10913792B2 (en)	2021-02-09
CA2884124A1 (en)	2014-03-27
EP2897977A1 (en)	2015-07-29
KR20230041086A (ko)	2023-03-23
WO2014044768A1 (en)	2014-03-27
CN109999195A (zh)	2019-07-12
IL237554A0 (en)	2015-04-30
KR20220028177A (ko)	2022-03-08
UA117228C2 (uk)	2018-07-10
US20210130451A1 (en)	2021-05-06
US20180230208A1 (en)	2018-08-16
IN2015KN00657A (zh)	2015-07-17
JP2022169709A (ja)	2022-11-09

Publication	Publication Date	Title
HK1208231A1 (zh)	2016-02-26	類風濕性關節炎之治療
HK1219414A1 (zh)	2017-04-07	治療關節炎的方法
EP2787497A4 (en)	2015-09-16	DEFAULT ASSESSMENT APPARATUS
GB201014633D0 (en)	2010-10-13	Rheumatoid arthritis treatment
EP2875825A4 (en)	2016-03-23	COMPOSITION FOR PREVENTING OR TREATING RHEUMATOID ARTHRITIS
EP2871630A4 (en)	2015-06-17	DEVICE FOR MONITORING MONITORING
HK1200855A1 (zh)	2015-08-14	類風濕性關節炎的治療
EP2833380A4 (en)	2015-04-08	REACTOR APPARATUS
GB201218666D0 (en)	2012-11-28	Apparatus
HUE045341T2 (hu)	2019-12-30	Úttisztító berendezés
GB2504133B (en)	2014-11-12	Improved apparatus
GB2502268B (en)	2015-05-13	Improved apparatus
EP2852559A4 (en)	2015-11-04	METHOD OF TREATING MUD
HK1249427A1 (zh)	2018-11-02	關節炎治療
GB201220673D0 (en)	2013-01-02	Apparatus
GB201300914D0 (en)	2013-03-06	Apparatus
GB201218575D0 (en)	2012-11-28	Nephroureterectomy apparatus
HK1209999A1 (zh)	2016-04-15	設備
GB201215796D0 (en)	2012-10-17	Apparatus
EP2929742A4 (en)	2015-12-23	TRACKING DEVICE
ZA201501559B (en)	2019-09-25	Treatment for rheumatoid arthritis
GB2513286B (en)	2018-02-28	Apparatus
GB201219911D0 (en)	2012-12-19	Arthritis pain reducer
HUP1200221A2 (en)	2013-10-28	Sludge treatment
GB201218041D0 (en)	2012-11-21	Methods compounds for preventing arthritis